Loqus23

Developer of oral small molecule therapies to treat neurodegenerative diseases

placeCambridge, England, United Kingdom calendar_todayFounded 2019 groups1 employees language loqus23.com

Registered entities

Social engagement

Social engagement: 2.2K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

4 investors on record; lead investors include SV Health Investors, Novartis Venture Fund, Forbion.

Investor typeCountShare
Venture capital4100%

Recent activity

6 Jan 2026
Milestone
regulatory
16 Dec 2025
Event
44th Annual J.P. Morgan Healthcare Conference
13 Nov 2025
Event
London Life Sciences Week (Jefferies Week)
Coming soon